跳至主要内容
临床试验/NCT03612323
NCT03612323Unknown早期 1 期

Comparative Evaluation of the Efficacy of Intra-ligamentary Injection of 20 Milligram (Mg) Piroxicam Versus 4% Articaine in Management of Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars

Cairo University0 个研究点目标入组 20 人开始时间: 2018年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
20
主要终点
Alleviation of post-operative pain severity

研究概览

简要总结

Comparing the efficacy of intra-ligamentary Piroxicam and intra-ligamentary Articaine on pain during and after endodontic treatment of mandibular molars with symptomatic irreversible pulpitis.

详细描述

Owing to the painful nature of endodontic treatment in teeth with symptomatic irreversible pulpitis and difficulty in achieving effective anesthesia particularly in mandibular molars due to various factors such as different bony landmarks, anatomical variations, needle deflection, accessory innervation, so local anesthesia isn't enough in such cases. Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral Piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment. It is also postulated that the intraligamentary injection enables the application of anti-inflammatory agents in the periapical intraosseous region. Moreover, intra-ligamentary injection of local anesthesia was reported to be an effective and easy way to control severe pain during endodontic treatment mainly in mandibular teeth which are more difficult than maxillary teeth , thus piroxicam may be effective as an adjuvant drug to support the action of local anesthetics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy and medically free patients.
  • Acute symptomatic irreversible pulpitis of the mandibular first or second molar teeth.
  • Vital teeth with no history of previous root canal treatment.
  • Teeth that could be treated endodontically in single visit.
  • Teeth with normal periodontium, not sensitive to percussion with no periapical radiolucency.
  • Patients able to understand numerical rating scale and sign the informed consent.

排除标准

  • Known hypersensitivity to piroxicam.
  • Pregnancy or lactation.
  • Asthma or allergy to other anti-inflammatory drugs.
  • History of peptic ulceration.
  • Teeth associated with swelling or fistulous tract, acute or chronic periapical abscess.

研究组 & 干预措施

Intra-ligamentary Piroxicam

Experimental

Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.

干预措施: Intra-ligamentary Piroxicam (Drug)

Intra-ligamentary Articaine

Active Comparator

Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine

干预措施: Intra-ligamentary Articaine (Drug)

结局指标

主要结局

Alleviation of post-operative pain severity

时间窗: up to 48 hours

the patient will be asked to rate the progress of pain on the NRS and inform the investigator with the results,Primary outcome will be collected by the operator through Numerical Rating Scale (NRS) which is an 11-point scale consisting of numbers from 0 through 10; 0 reading represents "no pain" , 1- 3 readings represent "mild pain" , 4- 6 readings represent "moderate pain" , 7- 10 readings represent "severe pain" No or mild pain will be considered as success while moderate or severe pain will be regarded as failure.

次要结局

  • Intra-operative pain during access cavity preparation and instrumentation which will be measured ny Numerical Rating Scale (NRS)(immediately after injection of the drug up to 2 hours till end of endodontic treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lobna Elhadad

Principal Investigator

Cairo University

相似试验